Literature DB >> 31586173

Deaths Associated With Hepatitis C Virus Infection Among Residents in 50 States and the District of Columbia, 2016-2017.

Kathleen N Ly1, Arialdi M Miniño2, Stephen J Liu3, Henry Roberts1, Elizabeth M Hughes1, John W Ward4, Ruth B Jiles1.   

Abstract

BACKGROUND: Mortality associated with hepatitis C virus (HCV) has been well-documented nationally, but an examination across regions and jurisdictions may inform health-care planning.
METHODS: To document HCV-associated deaths sub-nationally, we calculated age-adjusted, HCV-associated death rates and compared death rate ratios (DRRs) for 10 US regions, 50 states, and Washington, D.C., using the national rate and described rate changes between 2016 and 2017 to determine variability. We examined the mean age at HCV-associated death, and rates and proportions by sex, race/ethnicity, and birth year.
RESULTS: In 2017, there were 17 253 HCV-associated deaths, representing 4.13 (95% confidence interval [CI], 4.07-4.20) deaths/100 000 standard population, in a significant, 6.56% rate decline from 4.42 in 2016. Age-adjusted death rates significantly surpassed the US rate for the following jurisdictions: Oklahoma; Washington, D.C.; Oregon; New Mexico; Louisiana; Texas; Colorado; California; Kentucky; Tennessee; Arizona; and Washington (DRRs, 2.87, 2.77, 2.24, 1.62, 1.57, 1.46, 1.36, 1.35, 1.35, 1.35, 1.32, and 1.32, respectively; P < .05). Death rates ranged from a low of 1.60 (95% CI, 1.07-2.29) in Maine to a high of 11.84 (95% CI, 10.82-12.85) in Oklahoma. Death rates were highest among non-Hispanic (non-H) American Indians/Alaska Natives and non-H Blacks, both nationally and regionally. The mean age at death was 61.4 years (range, 56.6 years in West Virginia to 64.1 years in Washington, D.C.), and 78.6% of those who died were born during 1945-1965.
CONCLUSIONS: In 2016-2017, the national HCV-associated mortality declined but rates remained high in the Western and Southern regions and Washington, D.C., and among non-H American Indians/Alaska Natives, non-H Blacks, and Baby Boomers. These data can inform local prevention and control programs to reduce the HCV mortality burden. Published by Oxford University Press for the Infectious Diseases Society of America 2019.

Entities:  

Keywords:  hepatitis C; deaths; jurisdiction; mortality; region

Year:  2020        PMID: 31586173     DOI: 10.1093/cid/ciz976

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships.

Authors:  Damien C Tully; Judith A Hahn; David J Bean; Jennifer L Evans; Meghan D Morris; Kimberly Page; Todd M Allen
Journal:  Clin Infect Dis       Date:  2022-03-23       Impact factor: 20.999

2.  Hepatitis C mortality trends in San Francisco: can we reach elimination targets?

Authors:  Ali Mirzazadeh; Shelley N Facente; Katie Burk; James G Kahn; Meghan D Morris
Journal:  Ann Epidemiol       Date:  2021-10-23       Impact factor: 6.996

3.  Changes in liver-related mortality by etiology and sequelae: underlying versus multiple causes of death.

Authors:  Ming-Jen Sheu; Fu-Wen Liang; Ching-Yih Lin; Tsung-Hsueh Lu
Journal:  Popul Health Metr       Date:  2021-04-29

4.  A retrospective, descriptive study of hepatitis C testing, prevalence, and care continuum among adults on probation.

Authors:  Kevin F Kamis; David L Wyles; Matthew S Minturn; Tracy Scott; Dean McEwen; Hermione Hurley; Scott J Prendergast; Jessie Gunter; Sarah E Rowan
Journal:  Health Justice       Date:  2022-08-10

5.  "Caballo": risk environments, drug sharing and the emergence of a hepatitis C virus epidemic among people who inject drugs in Puerto Rico.

Authors:  R Abadie; K Dombrowski
Journal:  Harm Reduct J       Date:  2020-10-23

6.  Hepatitis C Testing and Linkage to Care Among Adults on Probation in a Large US City.

Authors:  Kevin F Kamis; David L Wyles; Matthew S Minturn; Tracy Scott; Dean McEwen; Hermione Hurley; Scott J Prendergast; Sarah E Rowan
Journal:  Open Forum Infect Dis       Date:  2021-12-16       Impact factor: 3.835

7.  County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.

Authors:  Eric W Hall; Sarah Schillie; Adam S Vaughan; Jeb Jones; Heather Bradley; Ben Lopman; Eli S Rosenberg; Patrick S Sullivan
Journal:  Hepatology       Date:  2021-07-20       Impact factor: 17.425

8.  Inhibitory activity of limonoids from Khaya grandifoliola C.DC (Meliaceae) against hepatitis C virus infection in vitro.

Authors:  Arnaud Fondjo Kouam; Frédéric Nico Njayou; Fei Yuan; Babayemi Olawale Oladejo; He Hongtao; Pierre Mkounga; Paul Fewou Moundipa
Journal:  Avicenna J Phytomed       Date:  2021 Jul-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.